The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group.
In a multicentre, randomized, double-blind controlled trial comparing the low-molecular-weight heparin enoxaparin (40 mg) with a standard unfractionated heparin (Ca-heparin, 3 x 5,000 U) in deep-vein thrombosis prophylaxis in a high-risk group of 959 hospitalized medical patients, enoxaparin was at least as efficacious as standard heparin, with fewer adverse events.
Lechler
E
E
Department of Internal Medicine, University of Cologne, Germany.
Schramm
W
W
Flosbach
C W
CW
D000368:Aged; D004311:Double-Blind Method; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007388:Internal Medicine / Q000379:methods*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013924:Thrombophlebitis / Q000453:epidemiology* / Q000517:prevention & control
D017984:Enoxaparin; D005343:Fibrinolytic Agents